LYR-220 Design 2 for Chronic Sinusitis

"Indeed, clinicaltrials.gov highlights that this trial is actively searching for participants. The study was initially listed on November 23rd 2021 and has been updated on October 25th 2022. 70 individuals need to be recruited from 21 separate sites."

"During the 28 week duration of this trial, Plasma MF concentrations will act as the primary measured outcome. Supplementary outcomes that are to be monitored include: Intraocular Pressure (IOP), Adverse Events and their severity, and Laboratory Values (hematology and chemistry)."

"LYR-220 Design 2's safety has been largely supported by data from Phase 2 trials, thus receiving a score of 2 on the scale. As such, efficacy is yet to be assessed."

"Presently, the trial is being conducted in 21 different medical centres across America. These sites are based in Baltimore, Carlsbad and Spokane as well as 18 other places of residence. In order to reduce travelling costs for participants, it may be prudent to select a centre closest to your home address."

"Indeed, according to information posted on clinicaltrials.gov, this study is actively enrolling participants. The initial posting date was November 23rd 2021 with the most recent amendment made on October 25th 2022."